Tablet: Adults 1-2 tablets every 4 to 6 hours up to a maximum of 4g (8 tablets) daily. Children (6-12 years) 1/2 to 1 tablet 3 to 4 times daily. Syrup and Suspension: Children (3 months to below 1 year) 1/2 to 1 teaspoonful 3 to 4 times daily. Children (1-5 years) 1-2 teaspoonful 3 to 4 times daily. Children (6-12 years) 2-4 teaspoonful 3 to 4 times daily. Adults: 4-8 teaspoonful 3 to 4 times daily. Paediatric Drops: Children (0-3 months): 0.5 ml. Children (4 to 11 months) 1.0 ml. Children (1 to 2 years) 1.5 ml. Dose can be repeated, every 4 hours.Suppository: Suppository should be administered rectaly. Children below (5 years) 125-250 mg, 4 times daily. Show more Preparation: Ace® Tablet: Each box contains 500 tablets in blister pack. Ace® XR Tablet: Each box contains 100 tablets in blister pack. Ace® Syrup (60 ml): 60 ml syrup in sealed cap PET bottle (with measuring cup). Ace® Syrup (100 ml): 100 ml syrup in sealed cap PET bottle (with measuring cup). Ace® Suspension: 60 ml suspension in sealed cap PET bottle. Ace® Paediatric drops (30 ml): 30 ml paediatric drop in sealed cap PET bottle (with dropper). Ace® 125 Suppository: Each box contains 20 suppositories in blister pack. Ace® 250 Suppository: Each box contains 20 suppositories in blister pack. Ace® 500 Suppository: Each box contains 20 suppositories in blister pack.
Product details of Acifix Tablet, 1 Strip [Rabeprazole sodium 20mg]
- Quantity number indicates strip. 10 pieces of tablets/strip
- Indicated for:Duodenal ulcers, Gastroesophageal Reflux Disease, Peptic ulcer disease, H. pylori infection, Paediatric GERD
Pregnancy category B. Cetirizine should be used in pregnancy only if clearly needed. Cetirizine has been reported to be excreted in human milk and thus, use of Cetirizine in lactating mother is not recommended. STORAGE CONDITION: Protect from direct light exposure. Store in dry place at a temperature not exceeding 300 C. Keep out of the reach of children. HOW SUPPLIED Alatrol® Tablet: Each box contains 100’s tablets. Alatrol® Syrup: Each bottle contains 60 ml syrup and a measuring cup. Alatrol® Paediatric Drops: Each bottle contains 15 ml paediatric drops and a calibrated dropper.
Dosage & Administration:Bicozin Syrup: Adults: 10 ml (2 teaspoonfuls) 2 to 3 times daily, Children: 10 ml (2 teaspoonfuls) 1 to 3 times daily, Infants: 5 ml (1 teaspoonful) 1 to 2 times daily. Bicozin Tablet: Preparation: Thiamine Hydrochloride 5 mg, Riboflavin 2 mg, Pyridoxine Hydrochloride 2 mg, Nicotinamide 20 mg and elemental Zinc 10 mg/5 ml Syrup. Thiamine Mononitrate 5 mg, Riboflavin 2 mg, Pyridoxine Hydrochloride 2 mg, Nicotinamide 20 mg & elemental Zinc 10 mg/Tablet.
Ceevit®COMPOSITION Ceevit®: Each tablet contains ascorbic acid BP and sodium ascorbate BP equivalent to 250 mg of ascorbic acid BP. PHARMACOLOGY Ceevit® (vitamin C) the water-soluble vitamin, is readily absorbed from the gastrointestinal tract and is widely distributed in the body tissues. It is believed to be involved in biological oxidations and reductions used in cellular respiration. It is essential for the synthesis of collagen and intracellular material. Vitamin C deficiency develops when the dietary intake is inadequate and when increased demand is not fulfilled. Deficiency leads to the development of well defined syndrome known as scurvy, which is characterized by capillary fragility, bleeding (especially from small blood vessels and the gums), anaemia, cartilage and bone lesions and slow healing of wounds. INDICATION Ceevit® is indicated for prevention and treatment of scurvy. It may be indicated in pregnancy, lactation, infection, trauma, burns, cold exposure, following surgery, fever, stress, peptic ulcer, cancer, methaemoglobinaemia and in infants receiving unfortified formulas. It is also prescribed for haematuria, dental caries, pyorrhea, acne, infertility, atherosclerosis, fractures, leg ulcers, hay fever, vascular thrombosis prevention, levodopa toxicity, succinyl-choline toxicity, arsenic toxicity etc. To reduce the risk of stroke in the elderly, long-term supplementation with Ceevit® is essential. DOSAGE AND ADMINISTRATION For the treatment of scurvy: 1-2 tablets daily; but dose may be increased depending on the severity of the condition. For the reduction of risk of stroke in the elderly: 1-2 tablets daily. In other cases: 1 tablet daily or as directed by the physician. Maximum safe dose is 2000 mg daily in divided doses. CONTRAINDICATION AND PRECAUTION Ingestion of megadose (more than 1000 mg daily) of vitamin C during pregnancy has resulted in scurvy in neonates. Vitamin C in mega-doses has Ascorbic acid and Sodium ascorbate Vitamin C Ceevit® VITAMINS been contraindicated for patients with hyperoxaluria. Vitamin C itself is a reactive substance in the redox system and can give rise to false positive reactions in certain analytical tests for glucose, uric acid, creatine and occult blood. SIDE EFFECT Vitamin C has little toxicity and only mega-doses of vitamin C may cause diarrhoea, abdominal bloating, iron over-absorption that is harmful in patients with thalassaemia, sideroblastic anemia, and haemochromatosis; hyperoxaluria, hyperuricosuria, and hemolysis in patients with glucose-6 phosphate dehydrogenase deficiency. A pregnant woman taking more than 5 g/day may suffer fetal abortion. DRUG INTERACTION Potentially hazardous interactions: Ascorbic acid is incompatible in solution with aminophylline, bleomycin, erythromycin, lactobionate, nafcillin, nitrofurantoin sodium, conjugated oestrogen, sodium bicarbonate, sulphafurazole diethanolamine, chloramphenicol sodium succinate, chlorthiazide sodium and hydrocortisone sodium succinate. Useful interactions: Ascorbic acid increases the apparent half-life of paracetamol and enhances iron absorption from the gastrointestinal tract. USE IN PREGNANCY AND LACTATION The drug is safe in normal doses in pregnant women, but a daily intake of 5 gm or more is reported to have caused abortion. The drug may be taken safely during lactation. STORAGE REQUIREMENT Should be stored in a dry place below 30°C. HOW SUPPLIED Ceevit®: Box containing 20 x 10 tablets in strip pack.
COMPOSITION Tablet: Each tablet containsDried Aluminium Hydroxide Gel BP 425.53 mg (Al2O3, 47% minimum) Magnesium Hydroxide BP 400 mg Simethicone USP 30 mg Suspension: Each 5 ml contains - Aluminium Oxide 200 mg (Equivalent amount of Aluminium Hydroxide Gel USP) Magnesium Hydroxide 400 mg (Equivalent amount of Magnesium Hydroxide Paste USP) Simethicone USP 30 mgPHARMACOLOGY Entacyd® Plus is the mixture of non-systemic acid neutralizing substances and antiflatulent. This preparation offers reliability as well as long action. Aluminium Hydroxide and Magnesium Hydroxide induce the relief of ulcer by neutralizing gastric acid secreted from parietal cells of the stomach. The clinical use of simethicone is based on its antifoam properties. Simethicone spreads on the surface of aqueous liquids, forming a film of low surface tension and causing collapse of foam bubbles. Simethicone repeatedly allows mucous surrounded gas bubbles in the GI tract to coalesce and be expelled. Entacyd® plus is used in the treatment of flatulence and meteorism for the elimination of gas, air or foam from the gastro-intestinal tract prior to radiography and for the relief of abdominal distension and dyspepsia. Simethicone is physiologically inert; it does not appeared to be absorbed from the GI tract to interfere with gastric secretion or absorption of nutrients. Following oral administration, the drug is excreted unchanged in the feces. INDICATION Entacyd® Plus is indicated for symptomatic relief of hyperacidity associated with the peptic ulcer, gastritis, peptic oesophagitis, gastric hyperacidity, heartburn, sour stomach or hiatus hernia. It is effective in the prevention of stress ulceration and GI bleeding. It acts as an antiflatulent to alleviate the symptoms of gas including post operative gas pain. Entacyd® Plus rapidly Aluminium Hydroxide, Magnesium Hydroxide, Simethicone Antacid, Antiulcerants Entacyd® Plus ALIMENTARY PREPARATIONS relieves acid pain, disperses gastric foam and facilitates eructation of gas and air. DOSAGE AND ADMINISTRATION Tablet: 1-2 tablets 1-3 hours after meal and at bed time or as directed by the physician. Suspension: 1-2 teaspoonful 1-3 hours after meal and at bedtime or as directed by the physician. CONTRAINDICATION AND PRECAUTION
Entacyd® Plus should not be administered in patients with renal failure or hypophosphataemia or in those who are severely debilitated. It is also contraindicated in alkalosis and hypermagnesaemia, where abdominal distention may be due to partial or complete intestinal obstruction. Entacyd® Plus should be used with caution in patients with kidney disease.SIDE EFFECT Gastrointestinal side effects are uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or regurgitation may occur. DRUG INTERACTION All antacids may increase or decrease the rate and/or extent of absorption of concomitantly administered oral drugs. Antacids decrease the bioavailability of theophyline, tetracycline, quinolone antibiotics, isoniazide, ketoconazole, ethambutol, some antimuscarinic drugs, benzodiazepines, phenothiazines, ranitidine, indomethacine, nitrofurantoin, fluoride, phosphate, propanolol, atenolol, digoxins, vitamins etc. Antacids increase the bioavailability of some drugs; e.g. sulphonamides, levodopa, valproic acid, enteric coated aspirin etc. USE IN PREGNANCY It is advised to avoid antacid preparations in the first trimester of pregnancy. STORAGE CONDITION Store in cool and dry place, out of reach of children. HOW SUPPLIED Entacyd® Plus tablet: Box containing 20 x 10 tablets in blister pack. Entacyd® Plus suspension: Bottle containing 200 ml suspension.
FexoTM 60: Each film coated tablet contains Fexofenadine Hydrochloride USP 60 mg. FFexoTM 120: Each film coated tablet contains Fexofenadine Hydrochloride USP 120 mg. FexoTM 180: Each film coated tablet contains Fexofenadine Hydrochloride USP 180 mg. FexoTM Suspension: Each 5 ml suspension contains Fexofenadine Hydrochloride USP 30 mg. PHARMACOLOGY Fexofenadine Hydrochloride is an antihistamine with selective peripheral H1-receptor antagonist activity. Fexofenadine is rapidly absorbed after oral doses with peak plasma concentrations being reached in 2-3 hours. It is about 60% to 70% bound to plasma proteins. About 5% of the total doses is metabolized, mostly by the intestinal mucosa, with only 0.5% to 1.5% of the dose undergoing hepatic biotransformation by the cyto-chrome P450 system. Elimination half-life of 14 hours has been reported although this may be prolonged in patients with renal impairment. Excretion is mainly in the faeces with only 10% being present in the urine. Fexofenadine does not appear to cross the blood-brain barrier.INDICATION Seasonal Allergic Rhinitis: FexoTM tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. FexoTM Oral Suspension is indicated for the relief of symptoms associated with seasonal allergic rhinitis in children 2 to 11 years of age. Symptoms to treat effectively: sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes. Chronic Idiopathic Urticaria: FexoTM tablets are indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. FexoTM Oral Suspension is indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 11 years of age. Fexofenadine Hydrochloride significantly reduces pruritus and the number of wheals. USE IN PREGNANCY AND LACTATION There are no adequate and well controlled studies in pregnant women. Fexofenadine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Fexofenadine is excreted in human milk or not. Caution should be exercised when Fexofenadine is administered to a nursing woman. DRUG INTERACTION Plasma concentrations of Fexofenadine have been increased when given with Erythromycin or Ketoconazole. Antacid containing Aluminium and Magnesium Hydroxide reduces the absorption of Fexofenadine. Fruit juices including grapesfruit may reduce the bioavailability of Fexofenadine and use together should be avoided. CONTRAINDICATION Fexofenadine is contraindicated in patients with known hypersensitivity to any of the ingredients. DOSAGE AND ADMINISTRATION In case of decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function. STORAGE CONDITION Tablet: Store at a cool and dry place, protected from light & moisture. Suspension: Store at a cool and dry place, protected from light. Keep out of the reach of children.
HOW SUPPLIED FexoTM 60: Each box contains 5 x 10 tablets in blister pack. FexoTM 120: Each box contains 5 x 10 tablets in blister pack. FexoTM 180: Each box contains 3 x 10 tablets in blister pack. FexoTM Susupension: Each bottle contains 50 ml suspension and calibrated dropper & measuring cup.
Rabeprazole Sodium is an antiulcerant drug in the class of Proton Pump Inhibitors. Rabeprazole Sodium is a substituted benzimidazole which suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase enzyme at the secretory surface of the gastric parietal cell. It is an enteric coated tablet, because of its coated formulation it is highly stable in stomach and because of higher pKa value of Rabeprazole Sodium it provides faster onset of action. It blocks the final step of gastric acid secretion. After oral administration of 20 mg, Rabeprazole is absorbed and can be detected in plasma by 1 hour. The effects of food on the absorption of Rabeprazole have not been evaluated. Rabeprazole is 96.3% bound to human plasma proteins. Rabeprazole is primarily metabolized in the liver by Cytochrome P-450 3A (Sulphone metabolite) and 2C19 (Desmethyl Rabeprazole). Following a single 20 mg oral dose of Rabeprazole, approximately 90% of the drug is eliminated in the urine.The remainder of the dose is excreted in the feaces.Dosage & Administration Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD): 20 mg to be taken once daily for 4 to 8 weeks. For those patients who have not healed after 8 weeks of treatment, an additional 8 week course may be considered. Maintenance of Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD Maintenance): The recommended adult oral dose is 20 mg once daily. Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD):The recommended adult oral dose is 20 mg once daily for 4 weeks. If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered. Healing of Duodenal Ulcers:The recommended adult oral dose is 20 mg once daily after the morning meal for a period up to four weeks. Most patients with duodenal ulcer heal within four weeks. A few patients may require additional therapy to achieve healing. Helicobacter pylori Eradication: To Reduce the Risk of Duodenal Ulcer Recurrence- Rabeprazole Sodium 20 mg Twice Daily for 7 Days Amoxicillin 1000 mg Twice Daily for 7 Days Clarithromycin 500 mg Twice Daily for 7 Days All three medications should be taken twice daily with the morning and evening meals. It is important that patients comply with the full 7-day regimen. Treatment of Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome: The dosage of Rabeprazole Sodium in patients with pathologic hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60 mg once a day. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100 mg QD and 60 mg BID have been administered. Some patients with Zollinger-Ellision syndrome have been treated continuously with Rabeprazole Sodium for up to one year. Interaction Rabeprazole is metabolized by the Cytochrome P-450 (CYP-450) drug metabolizing enzyme system. Rabeprazole does not have clinically significant interactions with other drugs metabolized by the CYP-450 system,such as Warfarin and Theophylline given as single oral dose, Diazepam as a single intravenous dose, and Phenytoin given as a single intravenous dose. In normal subjects, co-administration of Rabeprazole 20 mg QD resulted in an approximately 30% decrease in the bioavailability of Ketoconazole and increase in the AUC and Cmax for digoxin of 90% and 29% respectively. Contraindications Rabeprazole Sodium is contraindicated in patient with known hypersensitivity to Rabeprazole or to any component in the product. Side Effects Rabeprazole Sodium may sometimes cause headache, diarrhoea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness and dizziness. Pregnancy & Lactation Rabeprazole is FDA Pregnancy Category B. No data is available on administration of Rabeprazole to pregnant women. However this drug should be used during pregnancy, only if clearly needed. There are no data on the excretion of Rabeprazole into the breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the benefit of the drug to the mother. Precautions Administration of Rabeprazole Sodium to patients with mild to moderate liver impairment resulted in increased exposure and decreased elimination. Caution should be exercised in patients with severe hepatic impairment. Overdose Effects There has been no experience with large overdoses with Rabeprazole. No specific antidote for Rabeprazole is known. Rabeprazole is extensively protein bound and is not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive. Use in Special Population
Use in pediatric patients: The safety and effectiveness of Rabeprazole in pediatric patients have not been established. Storage Conditions Store below 25°C, protected from light and moisture. Keep all medicines out of the reach of the children.
PharmacologyEsomeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase in the gastric parietal cell. It is the S-isomer of omeprazole. Dosage
Tablet:Healing of erosive esophagitis: 20 mg or 40 mg once daily for 4 to 8 Weeks. For those patients who have not healed after 4-8 weeks of treatment, an additional 4-8 weeks course of Esomeprazole may be considered.
Long-term management of esophagitis: 20 mg once daily.Symptomatic gastroesophageal reflu X disease: 20 mg once daily for 4 weeks. H. pylori eradication for treatment of duodenal ulcer: Triple therapy: 20 mg Esomeprazole once daily with 500 mg Clarithromycin twice daily, and 1 g Amoxicillin twice daily for 7-10 days.
- Quantity number indicates 15 tablets in one strip.
- 1pcs tablets/strip
- Indicated for: Prophylaxis and chronic treatment of Asthma & for the symptomatic relief of Allergic Rhinitis
Product details of Monocast 5 Tablet, 1 Strip [Montelukast 5 mg]
- Quantity number indicates 1 strip.
- 1 strip contains 10 tablets..
- -Treatment of asthma